Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.
Under the agreement, Eidia gains access to Seegene's portfolio of multiplexed molecular diagnostics tests based on the company's tagging oligonucleotide capture and extension, or TOCE, technology.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
